Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03911128
Other study ID # ALLTogether1 pilot
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 29, 2019
Est. completion date August 2030

Study information

Verified date March 2024
Source Karolinska University Hospital
Contact Mats Heyman, M.D. PhD
Phone +46 8 517 704 07
Email mats.heyman@ki.se
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The pilot study collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new platform protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several randomised trials included in the study-design. The pilot study is implemented as a master protocol without study specific interventions, thus as an observational study. The pilot study is for countries/study-groups who intend to join ALLTogether1 (including experimental interventions). For these countries the pilot study is crucial to optimise diagnostics, registration systems, collaborations with vendors, logistics and data-checks before starting the main study. The study only includes "standard of care" treatment included in the master protocol.


Description:

The aims of the ALLTogether study are to improve survival and quality of survival for children and young adults with ALL. ALL in young people has excellent outcome with >90% survival in children and about 75% in young adults. However, patients still die of disease - after relapse as a result of under-treatment. Furthermore, a considerable fraction of younger patients are over-treated: All patients risk treatment-related death and some suffer long-term side-effects or secondary cancer. The rates of death from disease and death from therapy are almost the same for children. To show improvement with such good survival, large populations are needed. Study groups from the five Nordic countries, Estonia and Lithuania (NOPHO), the UK (UKALL), the Netherlands (DCOG), Germany (COALL), Belgium (BSPHO), Ireland (PHOAI), Portugal (SHOP) and France (SFCE) have designed a common treatment protocol as new standard of care for children and young adults with ALL. The risk-stratification is based on a novel, personalised algorithm using clinical characteristics, genetic changes in the leukaemia and response to therapy. The protocol will, based on a personalised risk-approach, define a platform for diagnosis and treatment onto which randomized as well as non-randomised interventions and translational studies can be added. This platform can also be used by countries joining the collaboration at a later date to prepare for full participation. High-risk B-lineage patients may be stratified to Chimeric Antigen Receptor T-cell (CAR-T) therapy as an alternative to high-risk blocks and stem-cell transplant to reduce the side-effects. Translational and other therapy-related research will be promoted by the common master protocol.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date August 2030
Est. primary completion date August 2028
Accepts healthy volunteers No
Gender All
Age group 0 Years to 45 Years
Eligibility Inclusion Criteria: - Patients newly diagnosed with T-lymphoblastic (T-cell) or B-lymphoblastic precursor (BCP) leukaemia (ALL) according to the WHO-classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition 2017) and with a diagnosis confirmed by an accredited laboratory at a participating paediatric oncology or adult haematology centre. - Age 0 - < 46 years (one day before 46th birthday) at the time of diagnosis, with the exception of infants with KMT2A-r BCP ALL (see exclusion criteria below). - Patients with surface immunoglobulin negative (sIG-) BCP-ALL and an IG::MYC rearrangement, unless they have a concurrent BCL2/6 rearrangement. T-ALL patients with MYC translocations. - Informed consent signed by the patient and/or parents/legal guardians according to country-specific age related guidelines - The ALL diagnosis should be confirmed by an accredited laboratory at a participating paediatric oncology or adult haematology centre. - The patient should be diagnosed and treated at a participating paediatric oncology or adult haematology centre in the participating countries. - The patient should be a resident in one of the participating countries on a permanent basis or should intend to settle in a participating country, for instance by an application for asylum. Patients who are visiting the country as tourists should not be included. However, returning expatriots and patients who intend to stay at least for the duration of the treatment with primary diagnosis abroad may be included if no treatment has been administered and the diagnostic procedures are repeated at a participating centre. - All women of childbearing potential (WOCBP) have to have a negative pregnancy test within 2 weeks prior to the start of treatment. Exclusion Criteria: - Age < 365 days and KMT2A-rearranged (KMT2A-r) BCP-ALL (documented presence of a KMT2A-split by FISH and/or a KMT2A fusion transcript). These patients will be transferred to an appropriate trial for infant KMT2A-r BCP-ALL, if available. - Age >45 years at diagnosis. - Patients with a previous malignant diagnosis (ALL as a second malignant neoplasm - SMN). - Relapse of ALL. - Patients with mature B-ALL (as defined by surface IG positivity) or any patients with IG::MYC and a concurrent BCL2/6 rearrangement. - Patients with Ph-positive ALL (documented presence of t(9;22)(q34;q11) and/or of the BCR::ABL1 fusion transcript). These patients will be transferred to an appropriate trial for t(9;22) if available. - Previously known ALL prone syndromes (e.g. Li-Fraumeni syndrome, germline ETV6 mutation), except for Down syndrome. Exploration for such ALL prone syndromes is not mandatory and patients in whom genetic work-up reveals a new germ-line mutation (index-cases) will remain in the study. - Treatment with systemic corticosteroids (>10mg/m2/day) for more than one week and/or other chemotherapeutic agents in a 4-week interval prior to diagnosis (pre-treatment). - Pre-existing contraindications to any treatment according to the ALLTogether protocol (constitutional or acquired disease prior to the diagnosis of ALL preventing adequate treatment). - Any other disease or condition, as determined by the investigator, which could interfere with the participation in the study according to the study protocol, or with the ability of the patients to cooperate and comply with the study procedures. - Women of childbearing potential who are pregnant at the time of diagnosis. - Women of childbearing potential and fertile men who are sexually active and are unwilling to use adequate contraception during therapy. Efficient birth control is required, see section 17.8. - Female patients, who are breast-feeding. - Essential data missing from the registration of characteristics at diagnosis (in consultation with the protocol chair).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Observational
Observational study - no intervention

Locations

Country Name City State
Denmark Aalborg University Hospital, Dept of Paediatrics Aalborg
Denmark Aarhus University Hospital Aarhus
Denmark Aarhus University Hospital, Child and Adolescent Health Aarhus
Denmark Rigshospitalet, Dept of Haematology Copenhagen
Denmark Rigshospitalet, Dept of Paediatrics Copenhagen
Denmark Odense University Hospital, Dept of Paediatrics Odense
Estonia North Estonia Medical Centre, Dept of Haematology Tallinn
Estonia Tallinn Children´s Hospital, Dept of Paediatrics Tallinn
Estonia Tartu University Hospital Tartu
Finland Helsinki University Hospital, Dept of Haematology Helsinki
Finland Helsinki University Hospital, Dept of Paediatrics Helsinki
Finland Kuopio University Hospital, Dept of Haematology Kuopio
Finland Kuopio University Hospital, Dept of Paediatrics Kuopio
Finland Oulu University Hospital, Dept of Haematology, Dept of Medicine Oulu
Finland Oulu University Hospital, Dept of Paediatrics Oulu
Finland Tampere University Hospital, Dept of Haematology Tampere
Finland Tampere University Hospital, Dept of Paediatrics Tampere
Finland Turku University Hospital, Clinical Haematology and Stem Cell Transplantation Unit Turku
Finland Turku University Hospital, Dept of Paediatrics Turku
Iceland Landspitali University Hospital, Children's Hospital Reykjavík
Lithuania Children's Hospital, Affiliate of Vilnius University Hospital Vilnius
Lithuania Vilnius University Hospital Vilnius
Norway Haukeland University Hospital, Dept of Haematology Bergen
Norway Haukeland University Hospital, Dept of Paediatrics Bergen
Norway Oslo University Hospital, Dept of Haematology Oslo
Norway Oslo University Hospital, Dept of paediatric haemato- and oncology Oslo
Norway Stavanger University Hospital, Dept of Haematology Stavanger
Norway University Hospital North Norway, Dept of Haematology Tromsø
Norway University Hospital of North Norway, Dept of Paediatrics Tromsø
Norway St. Olavs University Hospital, Dept of Haematology Trondheim
Norway St. Olavs University Hospital, Dept of Paediatrics Trondheim
Spain Hospital Universitario San Joan de Déu Barcelona
Spain Hospital Infantil Universitario Nino Jesus Madrid
Sweden Sahlgrenska University Hospital, Dept of Paediatric Haematology and Oncology Gothenburg
Sweden Sahlgrenska University Hospital, Section for Haematology and coagulation Gothenburg
Sweden Linköping University Hospital, Dept of Haematology Linköping
Sweden Linköping University Hospital, Dept of Paediatrics Linköping
Sweden Skåne University Hospital, Dept of Haematology Lund
Sweden Skåne University Hospital, Dept of Paediatrics Lund
Sweden Örebro University Hospital, Section for Haematology Örebro
Sweden Karolinska University Hospital, Dept of Paediatric Oncology and Haematology Stockholm
Sweden Karolinska University Hospital, Patient area Haematology Stockholm
Sweden Norrland University Hospital, Dept of Haematology Umeå
Sweden Norrland University Hospital, Dept of Paediatrics Umeå
Sweden Uppsala University Hospital, Dept of Haematology Uppsala
Sweden Uppsala University Hospital, Dept of Paediatric Haematology and Oncology Uppsala

Sponsors (4)

Lead Sponsor Collaborator
Mats Heyman NordForsk, Nordic Society for Pediatric Hematology and Oncology, The Swedish Childhood Cancer Foundation

Countries where clinical trial is conducted

Denmark,  Estonia,  Finland,  Iceland,  Lithuania,  Norway,  Spain,  Sweden, 

References & Publications (5)

Mondelaers V, Suciu S, De Moerloose B, Ferster A, Mazingue F, Plat G, Yakouben K, Uyttebroeck A, Lutz P, Costa V, Sirvent N, Plouvier E, Munzer M, Poiree M, Minckes O, Millot F, Plantaz D, Maes P, Hoyoux C, Cave H, Rohrlich P, Bertrand Y, Benoit Y; Children-s Leukemia Group (CLG) of the European Organization for Research and Treatment of Cancer (EORTC). Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951. Haematologica. 2017 Oct;102(10):1727-1738. doi: 10.3324/haematol.2017.165845. Epub 2017 Jul 27. — View Citation

Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E, Egeler RM, Hoogerbrugge P, Kaspers G, Van der Schoot E, De Haas V, Van Dongen J. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. J Clin Oncol. 2016 Aug 1;34(22):2591-601. doi: 10.1200/JCO.2015.64.6364. Epub 2016 Jun 6. — View Citation

Schramm F, Zimmermann M, Jorch N, Pekrun A, Borkhardt A, Imschweiler T, Christiansen H, Faber J, Feuchtinger T, Schmid I, Beron G, Horstmann MA, Escherich G. Daunorubicin during delayed intensification decreases the incidence of infectious complications - a randomized comparison in trial CoALL 08-09. Leuk Lymphoma. 2019 Jan;60(1):60-68. doi: 10.1080/10428194.2018.1473575. Epub 2018 Jul 3. — View Citation

Toft N, Birgens H, Abrahamsson J, Griskevicius L, Hallbook H, Heyman M, Klausen TW, Jonsson OG, Palk K, Pruunsild K, Quist-Paulsen P, Vaitkeviciene G, Vettenranta K, Asberg A, Frandsen TL, Marquart HV, Madsen HO, Noren-Nystrom U, Schmiegelow K. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018 Mar;32(3):606-615. doi: 10.1038/leu.2017.265. Epub 2017 Aug 18. — View Citation

Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, Rowntree C, Richards S. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013 Mar;14(3):199-209. doi: 10.1016/S1470-2045(12)70600-9. Epub 2013 Feb 7. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Event-free survival (EFS) compared to historical controls 5 year
Primary Overall survival (OS) compared to historical controls 5 year
See also
  Status Clinical Trial Phase
Unknown status NCT02360930 - Vincristine PK and PD in the AYA Population Compared to Younger Children N/A
Recruiting NCT05306301 - Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients Phase 2
Not yet recruiting NCT06101381 - CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma Phase 1/Phase 2
Terminated NCT02935543 - CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL Phase 2
Active, not recruiting NCT05440409 - CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL
Completed NCT02393859 - Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) Phase 3
Completed NCT05064787 - Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy N/A
Terminated NCT02435550 - iCare for Cancer Patients N/A
Completed NCT02799147 - GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia Phase 1/Phase 2
Terminated NCT02580981 - Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses N/A
Recruiting NCT04307576 - A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Phase 3
Completed NCT04942730 - Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) Phase 2
Terminated NCT01761682 - Acute Lymphoblastic Leukemia Registry at Asan Medical Center
Completed NCT04327037 - Safety of Expanded Haploidentical Natural Killer Cells for Leukemia Phase 1
Terminated NCT02349178 - Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT Phase 2
Recruiting NCT04209244 - Effect of Fish Oil on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia N/A
No longer available NCT00590915 - Erwinase Master Treatment Protocol N/A